Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Verastem, Inc.

Market Cap 362M 316M 292M 274M 513M 34.16B 516M 3.47B 1.34B 16.81B 1.36B 1.33B 58.39B P/E 2026 *
-2.64x
P/E 2027 * -3.8x
Enterprise Value 362M 316M 292M 274M 513M 34.16B 516M 3.47B 1.34B 16.81B 1.36B 1.33B 58.39B EV / Sales 2026 *
3.5x
EV / Sales 2027 * 1.98x
Free-Float
99.05%
Yield 2026 *
-
Yield 2027 * -
1 day-1.20%
1 week+4.57%
Current month-4.85%
1 month-3.29%
3 months-25.90%
6 months-46.84%
Current year-46.63%
1 week 3.85
Extreme 3.85
4.42
1 month 3.55
Extreme 3.55
4.53
Current year 3.55
Extreme 3.55
8.88
1 year 3.55
Extreme 3.55
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
58.56
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 31/07/2023
Director of Finance/CFO 39 30/10/2022
Chief Tech/Sci/R&D Officer - 17/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 31/07/2023
Director/Board Member 69 02/05/2017
Date Insider Type Main position Quantity % Market Cap.
05-20Free

Director

108,000 0.1229%
05-20Free

Director

36,000 0.0410%
05-20Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
-1.20%+4.57%-20.62%-59.92% 362M
+1.44%-1.25%+63.52%+114.88% 54.44B
+4.60%+5.82%+56.35%+43.04% 45.8B
-1.44%+1.51%-12.94%-19.24% 22.98B
-2.69%-0.95%-3.68%+379.00% 20.76B
+3.22%+2.94%+24.02%-35.05% 16.25B
+0.58%+1.08%+16.73%-38.06% 15.34B
-1.01%-2.97%+27.42%+171.92% 13.05B
+3.07%+5.43%+21.37% - 12.37B
+4.95%+13.49%+121.11%+249.05% 12.47B
Average +1.15%+2.42%+29.33%+89.51% 21.38B
Weighted average by Cap. +1.62%+1.39%+39.46%+98.41%

Financials

2026 *2027 *
Net sales 103M 90.23M 83.57M 78.23M 147M 9.77B 148M 991M 384M 4.81B 388M 380M 16.69B 183M 159M 148M 138M 259M 17.25B 261M 1.75B 679M 8.49B 686M 671M 29.48B
Net income -164M -143M -132M -124M -232M -15.45B -234M -1.57B -608M -7.61B -615M -602M -26.41B -137M -119M -110M -103M -194M -12.9B -195M -1.31B -507M -6.35B -513M -502M -22.04B
Net Debt - -
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
18/06/26 4.120 $ -1.20% 4,766,027
17/06/26 4.170 $ +3.99% 2,523,134
16/06/26 4.010 $ +0.25% 1,512,590
15/06/26 4.000 $ -2.44% 2,323,690
12/06/26 4.100 $ +4.06% 1,600,078
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.120USD
Average target price
16.00USD
Spread / Average Target
+288.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!